Dataset Information

Completeness map evaluation demonstrated with candidate next-generation cardiac CT architectures.

ABSTRACT: In this report, the authors introduce the general concept of the completeness map, as a means to evaluate the completeness of data acquired by a given CT system design (architecture and scan mode). They illustrate the utility of completeness map by applying the completeness map concept to a number of candidate CT system designs, as part of a study to advance the state-of-the-art in cardiac CT.In order to optimally reconstruct a point within a volume of interest (VOI), the Radon transform on all possible planes through that point should be measured. The authors quantified the extent to which this ideal condition is satisfied for the entire image volume. They first determined a Radon completeness number for each point in the VOI, as the percentage of possible planes that is actually measured. A completeness map is then defined as a 3D matrix of the completeness numbers for the entire VOI. The authors proposed algorithms to analyze the projection datasets in Radon space and compute the completeness number for a fixed point and apply these algorithms to various architectures and scan modes that they are evaluating. In this report, the authors consider four selected candidate architectures, operating with different scan modes, for a total of five system design alternatives. Each of these alternatives is evaluated using completeness map.If the detector size and cone angle are large enough to cover the entire cardiac VOI, a single-source circular scan can have ≥99% completeness over the entire VOI. However, only the central z-slice can be exactly reconstructed, which corresponds to 100% completeness. For a typical single-source architecture, if the detector is limited to an axial dimension of 40 mm, a helical scan needs about five rotations to form an exact reconstruction region covering the cardiac VOI, while a triple-source helical scan only requires two rotations, leading to a 2.5x improvement in temporal resolution. If the source and detector of an inverse-geometry (IGCT) system have the same axial extent, and the spacing of source points in the axial and transaxial directions is sufficiently small, the IGCT can also form an exact reconstruction region for the cardiac VOI. If the VOI can be covered by the x-ray beam in any view, a composite-circling scan can generate an exact reconstruction region covering the VOI.The completeness map evaluation provides useful information for selecting the next-generation cardiac CT system design. The proposed completeness map method provides a practical tool for analyzing complex scanning trajectories, where the theoretical image quality for some complex system designs is impossible to predict, without yet-undeveloped reconstruction algorithms.

SUBMITTER: Liu B

PROVIDER: S-EPMC3338591 | biostudies-other | 2012 May

REPOSITORIES: biostudies-other

ACCESS DATA

Similar Datasets

Project description:BACKGROUND: Pathway analysis of a set of genes represents an important area in large-scale omic data analysis. However, the application of traditional pathway enrichment methods to next-generation sequencing (NGS) data is prone to several potential biases, including genomic/genetic factors (e.g., the particular disease and gene length) and environmental factors (e.g., personal life-style and frequency and dosage of exposure to mutagens). Therefore, novel methods are urgently needed for these new data types, especially for individual-specific genome data. METHODOLOGY: In this study, we proposed a novel method for the pathway analysis of NGS mutation data by explicitly taking into account the gene-wise mutation rate. We estimated the gene-wise mutation rate based on the individual-specific background mutation rate along with the gene length. Taking the mutation rate as a weight for each gene, our weighted resampling strategy builds the null distribution for each pathway while matching the gene length patterns. The empirical P value obtained then provides an adjusted statistical evaluation. PRINCIPAL FINDINGS/CONCLUSIONS: We demonstrated our weighted resampling method to a lung adenocarcinomas dataset and a glioblastoma dataset, and compared it to other widely applied methods. By explicitly adjusting gene-length, the weighted resampling method performs as well as the standard methods for significant pathways with strong evidence. Importantly, our method could effectively reject many marginally significant pathways detected by standard methods, including several long-gene-based, cancer-unrelated pathways. We further demonstrated that by reducing such biases, pathway crosstalk for each individual and pathway co-mutation map across multiple individuals can be objectively explored and evaluated. This method performs pathway analysis in a sample-centered fashion, and provides an alternative way for accurate analysis of cancer-personalized genomes. It can be extended to other types of genomic data (genotyping and methylation) that have similar bias problems.

Project description:The advent of next generation sequencing technologies (NGS) has expanded the area of genomic research, offering high coverage and increased sensitivity over older microarray platforms. Although the current cost of next generation sequencing is still exceeding that of microarray approaches, the rapid advances in NGS will likely make it the platform of choice for future research in differential gene expression. Connectivity mapping is a procedure for examining the connections among diseases, genes and drugs by differential gene expression initially based on microarray technology, with which a large collection of compound-induced reference gene expression profiles have been accumulated. In this work, we aim to test the feasibility of incorporating NGS RNA-Seq data into the current connectivity mapping framework by utilizing the microarray based reference profiles and the construction of a differentially expressed gene signature from a NGS dataset. This would allow for the establishment of connections between the NGS gene signature and those microarray reference profiles, alleviating the associated incurring cost of re-creating drug profiles with NGS technology. We examined the connectivity mapping approach on a publicly available NGS dataset with androgen stimulation of LNCaP cells in order to extract candidate compounds that could inhibit the proliferative phenotype of LNCaP cells and to elucidate their potential in a laboratory setting. In addition, we also analyzed an independent microarray dataset of similar experimental settings. We found a high level of concordance between the top compounds identified using the gene signatures from the two datasets. The nicotine derivative cotinine was returned as the top candidate among the overlapping compounds with potential to suppress this proliferative phenotype. Subsequent lab experiments validated this connectivity mapping hit, showing that cotinine inhibits cell proliferation in an androgen dependent manner. Thus the results in this study suggest a promising prospect of integrating NGS data with connectivity mapping.

Dataset Information

Completeness map evaluation demonstrated with candidate next-generation cardiac CT architectures.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets